Luna Innovations (LUNA) & Accelerate Diagnostics (AXDX) Head to Head Review

Luna Innovations (NASDAQ: LUNA) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.


This table compares Luna Innovations and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luna Innovations 26.68% -1.99% -1.35%
Accelerate Diagnostics -1,520.99% -54.66% -51.90%

Earnings and Valuation

This table compares Luna Innovations and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Luna Innovations $59.21 million 1.21 -$2.36 million $0.43 5.88
Accelerate Diagnostics $4.18 million 330.22 -$64.02 million ($1.16) -21.34

Luna Innovations has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Luna Innovations and Accelerate Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luna Innovations 0 0 1 0 3.00
Accelerate Diagnostics 0 1 1 0 2.50

Luna Innovations currently has a consensus price target of $3.25, indicating a potential upside of 28.46%. Accelerate Diagnostics has a consensus price target of $33.00, indicating a potential upside of 33.33%. Given Accelerate Diagnostics’ higher probable upside, analysts clearly believe Accelerate Diagnostics is more favorable than Luna Innovations.

Risk & Volatility

Luna Innovations has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.

Institutional and Insider Ownership

18.1% of Luna Innovations shares are held by institutional investors. Comparatively, 44.9% of Accelerate Diagnostics shares are held by institutional investors. 13.0% of Luna Innovations shares are held by company insiders. Comparatively, 50.0% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Luna Innovations beats Accelerate Diagnostics on 8 of the 13 factors compared between the two stocks.

Luna Innovations Company Profile

Luna Innovations Incorporated develops, manufactures and markets fiber optic sensing and test, and measurement products. The Company is focused on bringing technology solutions to measure and monitor processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. The Company operates in two business segments: Products and Licensing, and Technology Development. The Products and Licensing segment develops, manufactures and markets its suite of products, including high-speed optical receiver (HSOR), custom optoelectronic subsystems (Optoelectronics), and Terahertz (THz) products, and fiber optic sensing, as well as test and measurement products. The Technology Development segment performs applied research principally in the areas of sensing and instrumentation, advanced materials and health sciences. The Company’s HSOR transmission products are deployed in the Internet communications equipment infrastructure for high-speed bandwidth.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings for Luna Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luna Innovations and related companies with's FREE daily email newsletter.

Leave a Reply